Navigation Links
Decongestant in OTC Cold Remedies Effective: FDA Panel
Date:12/14/2007

Current evidence says 10-milligram dose works, but advisers urge study of higher doses

FRIDAY, Dec. 14 (HealthDay News) -- A decongestant in many of the most popular over-the-counter cold medicines appears effective at its current dosage, U.S. health experts ruled Friday. But they also urged that more studies be done.

The panel of advisers to the U.S. Food and Drug Administration had heard day-long testimony on whether OTC cold medicines containing the decongestant phenylephrine really provide nasal congestion relief.

The medicines, which include Sudafed PE, Robitussin Night Relief Syrup, Tylenol Sinus and DayQuil capsules, all contain phenylephrine in a 10-milligram dose.

On Friday, members of the FDA's Nonprescription Drugs Advisory Committee voted 11-1 that existing evidence seems to support the effectiveness of phenylephrine at that dose.

In a second vote, 9-3, the panel urged further study of phenylephrine's safety and effectiveness at higher doses, including 25 milligrams, the Associated Press reported.

"What we know from the studies completed to date is that the 10- milligram dose is probably effective, but it's murky," said Yale University Professor Mary Tinetti, who chaired the panel.

The FDA is not required to follow the recommendations of its advisory panels, but it usually does.

Industry experts applauded the panel's vote.

Linda A. Suydam, president of the Consumer Healthcare Products Association, said in a prepared statement that the vote "reaffirms the results of numerous scientific studies and decades of consumer experience. CHPA and the leading makers of OTC cough, cold, and allergy medicines containing phenylephrine are committed to adding to the existing body of evidence currently supporting the safety and efficacy of phenylephrine."

She added, "Our goal is to continue to provide consumers with safe and effective therapies, and we are committed to working with FDA to ensure that the scientific data further supports this goal."

CHPA's members include Bayer, GlaxoSmithKline, Perrigo and most other makers of over-the-counter medicines, according to the AP.

The issue had been brought to the FDA by University of Florida researchers whose review of 14 studies on phenylephrine suggested that pill and syrup versions of these medicines offered users no real relief. The researchers had petitioned the FDA to investigate the matter and also examine the possibility of requiring higher doses that would work.

Drug companies have recently turned to phenylephrine as a replacement for another decongestant, pseudoephedrine, to comply with a 2006 U.S. law requiring that products containing pseudoephedrine be sold from behind the counter. The law was designed to prevent these medications from being bought in bulk and turned into methamphetamine.

On the academics' side, according to the AP, was drug maker Schering-Plough, which had decided not to reformulate its Claritin line of decongestants, which contain pseudoephedrine.

"If you have a stuffy nose, and you take an over-the-counter product containing phenylephrine, you will still not be able to breathe through your nose after you take it. That's the bottom line," Leslie Hendeles, a professor of pharmacy and pediatrics at the University of Florida, contended before the advisers met.

Hendeles had led the review, which was published in the July 2006 issue of the Journal of Allergy and Clinical Immunology, and he had petitioned the FDA to boost the maximum allowable dose of phenylephrine in oral decongestants to 25 milligrams, which he believes may be more effective.

"There needs to be a dose-response study where you look a 10-, 25- and 50-milligram doses and determine what dose would give you a relief of your stuffy nose without side effects," he said.

But one expert worried that boosting doses of phenylephrine might come at a price.

"No medicine ever has been shown beyond the shadow of a doubt to be effective for the common cold," noted Dr. Bruce Barrett, an associate professor of family medicine at the University of Wisconsin in Madison. "The main problem with decongestants is that they stimulate the heart and increase blood pressure."

Barrett is concerned that if the dose of phenylephrine is too high, it will result in increased blood pressure and other cardiac side effects.

"If applied to tens of thousands of people, you will get cardiac arrhythmias, some of them fatal," Barrett said. "The FDA may need to see studies of tens of thousands of people to see the severity of side effects, and the drug companies may not have the money to do that."

More information

For more about colds and flu, visit the American Lung Association.



SOURCES: Leslie Hendeles, Pharm.D., professor, pharmacy and pediatrics, University of Florida, Gainesville; Bruce Barrett, M.D., Ph.D., associate professor, family medicine, University of Wisconsin, Madison; Dec. 14, 2007, statement, Consumer Healthcare Products Association; Associated Press


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
2. Internet remedies for STIs pose significant public health hazard
3. Internists Diagnose Health Care System Ills, Prescribe Remedies to Achieve Universal Coverage, Better Quality, and Lower Costs
4. FDA Mulls Effectiveness of OTC Cold Remedies
5. FDA Panel Finds OTC Cold Remedies Effective
6. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
7. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
8. Patient Safety Authority Board of Directors Names Infection Advisory Panel
9. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
10. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
11. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Decongestant in OTC Cold Remedies Effective: FDA Panel
(Date:1/16/2017)... Battle Creek, MI (PRWEB) , ... January 17, 2017 , ... ... substance abuse located in Southwest Michigan, joined other volunteers and organizations in support of ... sees hundreds of children and families dressed up in colorful costumes of all designs ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show on ... Booth #2809. The SHOT Show is the shooting, hunting and outdoor trade show ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... , Antoine Dental Center, is currently offering complimentary consultations and financing for orthodontics ... teeth examined for bite irregularities and learn about their orthodontic options. Walk-in, late-evening, ...
(Date:1/16/2017)... ... 2017 , ... Specialty Technical Publishers (STP) and Specialty Technical ... (IAPC) EHS audit protocol for Singapore . Leading companies around the world ... obligations and rapidly collect, share, archive, and export audit findings in a cost ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher ... her nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, Global ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  OrthoAccel ® Technologies, ... (JCO) has published "The Effect of Vibration on ... Conducted by Dr. S. Jay Bowman , this ... II malocclusions, AcceleDent,s SoftPulse Technology ® speeds up ... also reducing the number of days to move the ...
(Date:1/17/2017)... , Jan 17, 2017 Research and Markets ... Healthcare Industry 2016-2020" report to their offering. ... The global fluoropolymer market in ... the period 2016-2020. Global Fluoropolymer Market in the ... analysis with inputs from industry experts. The report covers the market ...
(Date:1/17/2017)... 2017 Following an initial analysis, the ... Food and Drug Administration,s (FDA,s) final regulatory guidance ... by Pharmacies and Outsourcing Facilities." In its final ... pre-packaging -- which would have put patients at ... term care (LTC) pharmacies.  The ...
Breaking Medicine Technology: